Form 4 for HRTX HERON THERAPEUTICS, INC. /DE/
Accepted 2025-10-21 00:00:00 ET · period of report 2025-10-19 · accession 0001193125-25-244560 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-21 | 2025-10-19 | HRTX | Duarte Ira | EVP, CFO | M - OptEx | — | +3,874 | 168.1K | +2% | — |
| D | 2025-10-21 | 2025-10-19 | HRTX | Duarte Ira | EVP, CFO | M - OptEx | $0.00 | -3,874 | 34.9K | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-19 | M | A | 3,874 | — | 168,092 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock. |
| 2 | Derivative | Restricted Stock Units | 2025-10-19 | M | D | 3,874 | $0.00 | 34,869 | D | $0.00 · — to — | 3,874 Common Stock | (F2) The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (01/19/2024). |